
Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Under the deal, Zurich-based Vifor Pharma will pay $30m upfront, make a $30m equity investment in Angion Biomedica and hold out the prospect of...

German researchers find reason for remdesivir's inefficiency
“We have come to a simple conclusion,” said Max Planck Director Patrick Cramer at the MPI for Biophysical Chemistry. “Remdesivir does interfere with...

Biotech companies launch Biotech Austria
According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

BI initiates Phase II testing of COVID-19 drug
A new potential weapon against severe complications such as ARDS caused by the new coronavirus SARS-CoV-2 have been advanced by Boehringer Ingelheim...

COVID-19 test gives results within minutes
The method is published on MedRxiv, where the researchers headed by Professor Tim Dafforn from the University of Birmingham also...